The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.
May 2nd 2024
Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Analysis Determines Predictive Biomarkers for Lenalidomide Survival Benefits in Mantle Cell Lymphoma
May 19th 2023Polymorphic alleles of ABCB1 or VEGF were predictive of lenalidomide efficacy in patients with mantle cell lymphoma who received lenalidomide maintenance after autologous stem cell transplant.
Ibrutinib-Containing Regimens Remain of Interest Despite Agent’s Withdrawal in MCL and MZL
May 16th 2023Thomas M. Habermann, MD, expands on previous data that supported the initial accelerated approval of ibrutinib in marginal zone lymphoma and mantle cell lymphoma, phase 3 data leading to the agent’s voluntary withdrawal, and investigations of ibrutinib and other BTK inhibitors that could significantly change the treatment landscape in mantle cell lymphoma and marginal zone lymphoma.
Dr Habermann on the Withdrawal of U.S. Indications for Ibrutinib in MCL and MZL
May 12th 2023Thomas M. Habermann, MD, discusses the withdrawal of United States indications for ibrutinib in patients with mantle cell lymphoma who have previously received at least 1 therapy and in those with marginal zone lymphoma who require systemic treatment and have received at least 1 prior anti–CD20-based therapy.
Lisocabtagene maraleucel elicited statistically significant and clinically meaningful responses in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma, meeting the primary end point of the phase 2 TRANSCEND FL and phase 1 TRANSCEND NHL 001 trials, respectively.
AbbVie Withdraws Ibrutinib MCL and MZL Indications in the United States
AbbVie has announced the intention to voluntarily withdraw indications for ibrutinib in patients with mantle cell lymphoma who have previously received at least 1 therapy and in those with marginal zone lymphoma who require systemic treatment and have received at least 1 prior anti–CD20-based therapy.
Venetoclax Induces Notable ORR But Short PFS in High-Risk Mantle Cell Lymphoma
Venetoclax, alone or in combination with a BTK inhibitor, improved overall response rate in patients with pretreated, high-risk mantle cell lymphoma, according to findings from a retrospective study. However, the BCL-2 inhibitor was associated with short durations of progression-free survival.
Acalabrutinib Receives Approval in China for Relapsed/Refractory Mantle Cell Lymphoma
March 23rd 2023Acalabrutinib has received conditional approval from the National Medical Products Administration in China for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.
First-line ASCT Consolidation Confers Real-world Survival Benefit in Mantle Cell Lymphoma
Consolidative autologous stem cell transplant was associated with a statistically significant lower overall mortality risk and higher overall survival probability in patients with mantle cell lymphoma vs those who did not receive consolidation.
ASCT Following First Complete Remission Does Not Improve Real-World Survival in Mantle Cell Lymphoma
First-line consolidative autologous stem cell transplant following first complete remission, with or without maintenance rituximab, did not result in improved overall survival for patients with mantle cell lymphoma.
Dr. Mukherjee on Maintenance Rituximab in MCL
March 17th 2023Akash Mukherjee, MD, discusses the use of post-transplant maintenance rituximab in patients with mantle cell lymphoma who have received autologous stem cell transplant and considerations for using bendamustine/rituximab or BR plus cytarabine in elderly patients who are unfit for transplant.
Dr. Epstein-Peterson on Disease Observation and TP53 Mutations in MCL
March 16th 2023Zachary Epstein-Peterson, MD, discusses important updates in mantle cell lymphoma treatment, including the safety and feasibility of disease observation in patients with indolent MCL and the treatment of patients with TP53-mutated MCL.
Bispecific CD20/CD19-targeted CAR T-cell Therapies May Improve Outcomes in MCL
March 15th 2023Nirav N. Shah, MD, explains the choice to evaluate LV20.19 CAR in MCL, key efficacy and safety data from the follow-up study of this agent, and ongoing efforts to potentially expand its use across other B-cell malignancies.
Dr. Shah on the Safety of LV20.19 CAR T-cell Therapy in R/R MCL
March 6th 2023Nirav N. Shah, MD, discusses the safety of the lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens, as well as future efforts from a phase 1/2 study of the product in patients with relapsed/refractory mantle cell lymphoma.
Wang Details Caveats to Standards of Care for Treating Patients With MCL
February 28th 2023When treating patients with mantle cell lymphoma, early identification and appropriate frontline therapy remains critical, and therapies may vary for those 65 years and older compared with patients under the age of 65, with several additional factors also having a role in approaching treatment options for a new patient in the clinic.